CVS Health

CVS’s moat rests on scale, integration, and brand ubiquity across three pillars: Aetna insurance, Caremark PBM, and retail pharmacy and clinics.

Intangible assets: 60/100. The CVS and Aetna brands have trust and distribution advantages and benefit from plan design steering and preferred networks, but they do not prevent switching in commoditized categories or defend against regulatory change.

Switching costs: 55/100. Employer and plan sponsor switching costs in PBM are moderate, and insurance switching is seasonal but feasible; retail pharmacy has low switching friction for consumers.

Network effects: 45/100. There is some two‑sided scale in PBM (manufacturers and plan sponsors), yet it looks more like bargaining leverage than a classic network effect and is structurally exposed to policy reforms.

Cost advantages: 65/100. Scale procurement and dispensing economics are real in Caremark and retail, and Aetna’s membership base supports administrative leverage; however, reimbursement pressure and utilization spikes can quickly compress margins.

Efficient scale: 60/100. In PBM and specialty pharmacy the market is concentrated among three players, suggesting efficient scale, but rising transparency tools, alternative PBMs, and regulatory scrutiny erode durability.

Overall moat durability is weakened by 2024–2025 shocks (Medicare utilization, PBM investigations) and the dilution from care‑delivery losses. CVS retains advantages of breadth and contracting scale, but these are less durable than the strongest toll‑booth franchises we prefer.